Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Six Tricaprilin Formulations
NCT03635879Phase 1Withdrawn
- Sponsor
- Cerecin
- Start
- Feb 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of tricaprilin in Alzheimer's disease (AD) (6 arms), sponsored by Cerecin. Primary endpoints: Total ketones at 1 day, B-hydroxybutyrate at 1 day and 1 more. Planned start Feb 2019; status: withdrawn.
02
Drugs
tricaprilin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03635879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03635879.